Pfizer and Merck will jointly sell the lung cancer drug clozatinib

Source: Ding Xiangyuan, April 10, 2015, Pfizer and Merck, Germany, recently announced a deal between the two companies According to the deal, the two companies will jointly market Pfizer's lung cancer drug, clozatinib According to the information provided by the two pharmaceutical companies, the joint promotion will be carried out in two stages The first stage will start in the second and third quarter of this year from the United States and Canada At that time, the ALK inhibitor will be sold by Merck's schalano in Germany, as well as in Japan, France, Germany, Italy, Spain and the United Kingdom The second phase will start in 2016, including China and Turkey According to the terms of the agreement reached, Merck in Germany will receive the return related to the promotion of clozatinib in 2015, and the profit share of the drug will be obtained from the next year, including 80% for Pfizer and 20% for Merck in Germany The two companies plan to jointly promote clozatinib in the United States, Canada, Japan and five European Union countries by the end of 2020, while in China and Turkey, the two companies will start to jointly sell the drug in January 2016, and by the end of 2021, Pfizer will report the sales of the drug in the countries where the two companies jointly sell the drug Pfizer and Merck pointed out that the agreement is related to the Strategic Alliance announced by the two companies for the global development and commercialization of avelumab, a German Merck anti-PD-L1 antibody test drug previously known as msb010718c, which is used for a variety of cancer indications Schiermeier, global cancer director of Merck in Germany commented that "as the two companies advance avelumab, the cooperation of czotinib will allow us to establish joint tumor sales organizations in major markets," and pointed out that this agreement is very important for Merck in Germany, because it makes it possible to establish joint tumor sales organizations in avelumab Before putting it on the market, we accelerated the construction of our tumor sales team in the United States and Canada The two companies said that clozatinib is the first ALK inhibitor approved in the United States, the European Union and Japan, where it is used for the treatment of non-small cell lung cancer.